Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[2-(1-Formyl-2-Methyl-Propyl)-1-(4-Piperidin-1-Yl-but-2-Enoyl)-Pyrrolidin-3-Yl]-Methanesulfonamide
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
N-[2-(1-formyl–methyl-propyl)–(4-piperidin–but-enoyl)–pyrrolidin–methanesulfonamide is a synthetic small molecule sulfonamide compound with the molecular formula C19H33N3O4S and a molecular weight of approximately 399.6 g/mol[1][5]. It is catalogued as DB03890 in DrugBank and as ligand "616" in structural biology databases[9][10]. The compound features a pyrrolidine core substituted with both an enoylpiperidine side chain and a formyl-methylpropyl group, capped by a methanesulfonamide moiety. There are no approved medical indications or known clinical uses for this molecule; it is classified as experimental and has not been reported in clinical trials or regulatory filings[7]. Its mechanism of action and biological targets have not been described in public sources.
- Other names
- N-[2-(1-FORMYL-2-METHYL-PROPYL)-1-(4-PIPERIDIN-1-YL-BUT-2-ENOYL)-PYRROLIDIN-3-YL]-METHANESULFONAMIDEN-{(2S,3R)-2-[(2S)-3-methyl-1-oxobutan-2yl]-1[(2E)4(piperidin 1 yl)but 2 enoyl]pyrrolidin 3 yl}methanesulfonamideN-{(2S,3R)-22S33methyl 10xo 22butanyl11(20E)44(10pipéridinyl)22butenoyl33pyrrolidiny}méthanesulfonamide
Beyond the preview
Go deeper on N-[2-(1-Formyl-2-Methyl-Propyl)-1-(4-Piperidin-1-Yl-but-2-Enoyl)-Pyrrolidin-3-Yl]-Methanesulfonamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-[2-(1-Formyl-2-Methyl-Propyl)-1-(4-Piperidin-1-Yl-but-2-Enoyl)-Pyrrolidin-3-Yl]-Methanesulfonamide.